Frontiers | One fold, many functions—M23 family of peptidoglycan hydrolases
Untitled
Micreos Raises €30 Million for Endolysin Technology Set to Replace Antibiotics
Micreos initiates clinical trial to evaluate world's first endolysin-drug as a therapy for Atopic Dermatitis
New treatment option for eczema patients: Clinical study proves safe anti-S. aureus endolysin 'Staphefekt SA.100' significantly reduces eczema symptoms
Gladskin: Revolutionizing Eczema Care & Restoring Skin Health
Reena Rupani, MD, FAAD | LinkedIn
Gladskin: Revolutionizing Eczema Care & Restoring Skin Health
Micreos Raises €30 Million for Endolysin Technology Set to Replace Antibiotics
Gladskin | LinkedIn
Frontiers | One fold, many functions—M23 family of peptidoglycan hydrolases
Frontiers | Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections
Gladskin: Revolutionizing Eczema Care & Restoring Skin Health
Gladskin: Revolutionizing Eczema Care & Restoring Skin Health
Frontiers | Tracking the phage trends: A comprehensive review of applications in therapy and food production
Gladskin: Revolutionizing Eczema Care & Restoring Skin Health
Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances | Journal of Medicinal Chemistry
Mobile Elements Harboring Heavy Metal and Bacitracin Resistance Genes Are Common among Listeria monocytogenes Strains Persisting on Dairy Farms | mSphere
Introducing Gladskin Eczema Cream with Micreobalance™: A Swiss Scientific Breakthrough that Reduces Eczema Itch and Redness, Moisturizes while Rebalancing the Skin Microbiome in a Smarter and Safer Way
Frontiers | One fold, many functions—M23 family of peptidoglycan hydrolases
Introducing Gladskin Eczema Cream with Micreobalance™: A Swiss Scientific Breakthrough that Reduces Eczema Itch and Redness, Moisturizes while Rebalancing the Skin Microbiome in a Smarter and Safer Way
Frontiers | One fold, many functions—M23 family of peptidoglycan hydrolases
Gladskin | LinkedIn
New treatment option for eczema patients: Clinical study proves safe anti-S. aureus endolysin 'Staphefekt SA.100' significantly reduces eczema symptoms
New treatment option for eczema patients: Clinical study proves safe anti-S. aureus endolysin 'Staphefekt SA.100' significantly reduces eczema symptoms
